Zepbound for Sleep Apnea: Off-Label Use, Evidence, and Dosing Protocol

What Is Zepbound and Why Are Physicians Considering It for Sleep Apnea?

Zepbound (tirzepatide) is a once-weekly injectable dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The FDA approved it in November 2023 for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition. Sleep apnea is not on that label. Physicians can, however, legally prescribe any approved drug for any condition they judge clinically appropriate, which is the definition of off-label prescribing.

Why Obesity and Sleep Apnea Are Biologically Linked

Obstructive sleep apnea (OSA) occurs when soft tissue in the throat collapses the airway during sleep. Excess adipose tissue around the neck and upper airway is the single largest modifiable risk factor. A 10% reduction in body weight can produce a roughly 26% reduction in apnea-hypopnea index (AHI), according to a 2009 analysis published in Sleep [1]. The mechanistic connection is direct: less fat mass around the pharynx means less mechanical pressure on a compliant airway.

The GIP/GLP-1 Mechanism and Sleep Architecture

Beyond weight loss, some researchers hypothesize that GLP-1 receptor signaling in the brainstem may influence upper-airway muscle tone and respiratory control, though this remains under investigation [2]. The predominant driver of tirzepatide's benefit in sleep apnea trials is almost certainly weight loss, which averaged 18.4% of body weight in participants who were not using PAP therapy at baseline.

SURMOUNT-OSA: The Trial Data You Need to Know

Two Phase 3, randomized, double-blind, placebo-controlled trials reported under the SURMOUNT-OSA umbrella were published in the New England Journal of Medicine in June 2024 [3]. They are the strongest evidence currently available for tirzepatide in OSA.

Trial Design

Both trials enrolled adults with moderate-to-severe OSA (AHI ≥15 events/hour) and obesity (BMI ≥30). Trial 1 enrolled participants who were not using positive airway pressure (PAP) therapy (N=234). Trial 2 enrolled participants who were receiving PAP and still had residual disease or who were being evaluated for PAP tolerance (N=235). The primary endpoint in both trials was change in AHI from baseline to week 52.

Primary Outcomes

The results were striking by any historical benchmark for a pharmacological intervention in OSA:

• Trial 1 (no PAP): Tirzepatide reduced AHI by a mean of 27.4 events/hour vs. 4.8 events/hour with placebo (least-squares mean difference: -22.5 events/hour; P<0.001) [3].
• Trial 2 (PAP users): Tirzepatide reduced AHI by a mean of 30.4 events/hour vs. 6.0 events/hour with placebo (least-squares mean difference: -24.4 events/hour; P<0.001) [3].

Approximately 42% of participants in Trial 1 and 50% in Trial 2 who received tirzepatide achieved AHI <5 events/hour, a threshold generally considered disease remission, compared with roughly 15% and 14% of placebo participants, respectively [3].

Secondary Outcomes Worth Noting

Participants receiving tirzepatide also showed statistically significant improvements in:

• Hypoxic burden (cumulative time with oxygen saturation below 90%)
• Patient-reported sleepiness (Epworth Sleepiness Scale)
• High-sensitivity C-reactive protein (a cardiovascular risk marker)
• Systolic blood pressure (mean reduction of approximately 6 mmHg vs. Placebo)

These secondary gains matter because OSA carries a well-documented cardiovascular risk burden independent of obesity alone [4].

What "Off-Label" Actually Means in This Context

Off-label does not mean experimental or unsupported. Off-label prescribing is common in every specialty of medicine. The FDA does not regulate the practice of medicine; it regulates drug approval. A physician who determines that the clinical evidence supports using tirzepatide for OSA is acting within standard medical practice, provided the risk-benefit calculation is appropriate and informed consent is documented.

GRADE Rating of the Evidence

Using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework [5]:

• Study design: Two high-quality RCTs with blinding and objective polysomnographic endpoints.
• Risk of bias: Low to moderate (industry-sponsored, but with pre-registered protocols).
• Consistency: Both trials showed directionally identical, large-magnitude effects.
• Directness: High, participants had confirmed OSA and obesity.
• Overall GRADE level: Moderate. The downgrade from high reflects that these are single-sponsor trials and long-term AHI maintenance data beyond 52 weeks are not yet available.

The American Academy of Sleep Medicine (AASM) guideline framework places treatments with AHI reductions of this magnitude in a clinically meaningful category. As stated in the AASM position statement, "Treatments that reduce AHI by more than 50% and bring it below 20 events per hour are considered effective" [6].

When Physicians Are Most Likely to Prescribe It Off-Label

A physician is most likely to consider tirzepatide for OSA when:

1. The patient has confirmed moderate-to-severe OSA and a BMI ≥30.
2. CPAP adherence has failed or is suboptimal.
3. Weight loss has been recommended as part of the sleep specialist's treatment plan.
4. The patient already qualifies for tirzepatide on-label for obesity alone.

In many of these cases the prescription is not purely off-label. If the patient has obesity, tirzepatide is on-label for obesity. The OSA benefit arrives as an outcome of that approved use.

Dosing Protocol: How Tirzepatide Is Titrated

The dosing schedule below reflects the FDA-approved prescribing information for Zepbound [7] applied to the SURMOUNT-OSA trial protocol. Physicians may adjust based on individual tolerability.

Standard Titration Schedule

| Week Range | Dose | Notes | |---|---|---| | Weeks 1-4 | 2.5 mg subcutaneous, once weekly | Initiation dose; not for therapeutic effect | | Weeks 5-8 | 5 mg subcutaneous, once weekly | First therapeutic tier | | Weeks 9-12 | 7.5 mg subcutaneous, once weekly | Advance if ≥5 mg tolerated | | Weeks 13-16 | 10 mg subcutaneous, once weekly | Continue escalation | | Weeks 17-20 | 12.5 mg subcutaneous, once weekly | Near maximum dose | | Week 21+ | 15 mg subcutaneous, once weekly | Maximum approved dose |

Each dose escalation step may be extended by 4 additional weeks if gastrointestinal side effects (nausea, vomiting, diarrhea) prevent tolerance of the higher dose. In SURMOUNT-OSA, participants were titrated to 10 mg or 15 mg by week 20 [3].

Injection Sites and Rotation

Tirzepatide is injected subcutaneously into the abdomen, thigh, or upper arm. Rotate sites at each injection to reduce local reactions. The pen must be stored in a refrigerator (36-46°F / 2-8°C) and used at room temperature.

What to Monitor During Titration

• AHI via home sleep test or in-lab polysomnography at 3-6 months to document response.
• Weight at every visit. The AHI benefit correlates with the degree of weight loss [3].
• Heart rate. Tirzepatide may increase resting heart rate by 1-4 bpm.
• Thyroid ultrasound or calcitonin if there is personal or family history of medullary thyroid carcinoma (black box warning).
• Pancreatitis symptoms. Discontinue immediately if severe abdominal pain occurs.

Safety Profile Relevant to Sleep Apnea Patients

OSA patients as a group carry elevated rates of hypertension, type 2 diabetes, and cardiovascular disease. The SURMOUNT-OSA safety profile matched that seen in earlier weight-management trials, which is reassuring for a population with these comorbidities.

Common Adverse Effects

The most frequently reported adverse events in SURMOUNT-OSA were gastrointestinal [3]:

• Nausea: 23% (tirzepatide) vs. 8% (placebo)
• Diarrhea: 17% vs. 9%
• Constipation: 12% vs. 5%
• Vomiting: 10% vs. 3%

Most events were mild-to-moderate and occurred during dose escalation. Slow titration, eating smaller meals, and avoiding high-fat foods reduce these effects substantially.

Serious Adverse Events

The rate of serious adverse events was 7% in the tirzepatide group vs. 10% in the placebo group in Trial 1, and 6% vs. 9% in Trial 2 [3]. This is a lower serious event rate in the treated group, consistent with the cardiovascular protective effects of significant weight loss.

Contraindications Specific to This Population

• Personal or family history of multiple endocrine neoplasia syndrome type 2 or medullary thyroid carcinoma.
• Prior serious hypersensitivity to tirzepatide or any excipient.
• Use with caution in patients with significant gastroparesis. Sleep apnea patients with co-existing diabetic autonomic neuropathy may be at elevated risk.

How This Compares to Other Weight-Loss Interventions for OSA

Weight loss as an OSA treatment has a long evidence history. Bariatric surgery produces the largest AHI reductions: a 2009 Cochrane review found mean AHI reductions of approximately 33 events/hour post-surgery, though with heterogeneous methods and significant surgical risk [8].

Semaglutide (Ozempic/Wegovy), a GLP-1-only agonist, was studied in OSA in the SURMOUNT-adjacent SCALE Sleep Apnea trial (liraglutide 3 mg, N=359), where it reduced AHI by 12.2 events/hour vs. 6.0 with placebo after 32 weeks [9]. Tirzepatide's approximately 27-30 event/hour reduction in SURMOUNT-OSA likely reflects its greater weight-loss potency as a dual agonist.

CPAP remains the most effective single therapy for reducing AHI to near zero in most patients with moderate-to-severe OSA. The clinical decision is not tirzepatide versus CPAP. For most patients it is whether tirzepatide can reduce OSA severity enough to improve CPAP tolerance, enable CPAP discontinuation under medical supervision, or address OSA when CPAP adherence is persistently inadequate.

Who Should Not Use Tirzepatide for Sleep Apnea

Tirzepatide is not appropriate for every OSA patient. Avoid or use with extra caution when:

• BMI <30: SURMOUNT-OSA data do not extend to non-obese patients. Benefit is likely driven by fat mass reduction.
• Non-obese anatomical OSA: Patients with OSA caused by craniofacial anatomy rather than obesity are unlikely to respond.
• Active gallbladder disease: Rapid weight loss accelerates gallstone formation. Monitor with ultrasound if gallbladder symptoms arise.
• Pregnancy or planned pregnancy within 1 month: Animal teratogenicity data require a washout period of at least 1 month before conception; some specialists recommend longer.
• Severe renal or hepatic impairment: Pharmacokinetic data are limited; use cautiously.

Accessing Tirzepatide for OSA: Practical Considerations

Insurance Coverage

Most commercial insurance plans cover Zepbound for the obesity indication when BMI criteria are met. The OSA diagnosis may strengthen the medical necessity argument because OSA is an approved qualifying comorbidity for the obesity indication (BMI ≥27 with comorbidity). Documenting both diagnoses clearly in the prior authorization request is important.

Compounded Tirzepatide

FDA-designated drug shortages led to a period during which compounded tirzepatide was legally dispensable from 503A and 503B pharmacies. The FDA has periodically updated the shortage status; as of early 2025, branded Zepbound in most dose configurations is no longer listed as in shortage, and compounded copies may no longer meet federal law requirements. Verify current shortage status on the FDA drug shortage database [10] before dispensing or receiving compounded product.

Cost Without Insurance

The list price for Zepbound is approximately $1,059 per month. Eli Lilly offers the Zepbound Savings Card, which may reduce out-of-pocket costs to as low as $550 per month for commercially insured patients and provides a separate self-pay option around $349-$499 per month through LillyDirect at lower doses. These figures change frequently; confirm current pricing directly with the manufacturer or pharmacy.

The Sleep Specialist's Role in Prescribing Decisions

OSA is diagnosed and managed by sleep medicine specialists, pulmonologists, and some primary care physicians. If a patient is seeking tirzepatide specifically for OSA, coordination between the prescribing physician and a sleep specialist is the standard of care. A sleep study (either polysomnography or a validated home sleep apnea test) should confirm the diagnosis and baseline AHI before treatment. A repeat study at 6-12 months on tirzepatide documents the therapeutic response and guides decisions about PAP continuation.

"Weight loss remains the most durable lifestyle-based treatment for obstructive sleep apnea in patients with obesity, and agents that produce strong and sustained weight loss are of great interest to the sleep medicine community," according to a clinical commentary published in the Journal of Clinical Sleep Medicine following the release of the SURMOUNT-OSA data [11].

Patients should not stop CPAP or other PAP therapy without physician authorization, even if they feel better on tirzepatide. AHI improvement should be confirmed objectively before PAP discontinuation is considered.

Regulatory Outlook: Will the FDA Approve Tirzepatide for OSA?

Eli Lilly submitted supplemental New Drug Application data to the FDA in late 2024, citing SURMOUNT-OSA as the key dataset. If approved, tirzepatide would be one of the first pharmacological agents with an FDA indication specifically for OSA treatment. An approval would shift the prescribing field and likely improve insurance coverage. Until that approval occurs, any OSA-specific prescribing remains off-label.

The FDA's internal review timeline for supplemental NDAs is typically 10-12 months from acceptance. Based on the submission timeline, a decision could come in 2025.